You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Novel Flexible Access Port for Extra-Cardiac Beating Heart Repair
SBC: Nido Surgical, Inc Topic: NHLBIABSTRACT The overall goal of this Phase I STTR project is to develop an epicardial endoscopic instrumentCardioPort ECfor safe and precise dissection and stabilization of the heart surface to enable epicardial ablation of ventricular arrhythmiasEffective treatment of ventricular tachycardiaa lifethreatening arrhythmiain patients with ischemic heart disease often requires both endocardial and epicar ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques
SBC: Navidea Biopharmaceuticals, Inc. Topic: NHLBIMyocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.
SBC: Vova Ida, LLC Topic: 999SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Discovery of TrkC agonist antibodies for hearing loss
SBC: Zebra Biologics, Inc. Topic: NIDCD! Project Summary AbstractSensori neural hearing lossSNHLis caused by several factorsincluding excessive noisedrug toxin exposure and genetic lesionsTaken togetherhearing deficits represent the number one neurological disorder worldwideDespite numerous past and ongoing clinical studies there is currently no effective therapeutic treatment for hearing loss and its associated decline in quality of l ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Improving ALS Diagnosis using Needle I-EMG
SBC: Haystack Diagnostics, Inc. Topic: 103PROJECT SUMMARY Needle electromyographyEMGremains the standard approach for assessing neuromuscular diseaseWhile the technique has proven to be clinically valuable over the lastyearsit has important limitationsThese include its not being sensitive to alterations in muscle composition and structureits inability to assess the contractile apparatus of muscleand its subjective nature with an inter rat ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development and evaluation of diffuse correlation spectroscopy to monitor cerebral blood flow and detect intraventricular hemorrhage in extremely premature infants
SBC: 149 Medical Inc. Topic: 103PROJECT SUMMARY ABSTRACT Every year in the United States aboutof theinfants born extremely prematureandltweeks gestational age and andltg birth weightELGAdevelop intraventricular hemorrhageIVHIVH is associated with high risk for cerebral palsy and significant intellectual disabilitycausing lifelong implications for affected children and their families and considerable economic burdenIVH is caused ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Unbiased longitudinal neuromorphometry for clinical decision support
SBC: CORTICOMETRICS LLC Topic: NIAProject Summary Normal human neuroanatomy is incredibly variableand increases with ageThis impedes the ability of neuroimaging to detect effects in neurological conditions such as Alzheimerandapos s diseaseADHuntingtonandapos s diseaseHDmultiple sclerosisMSand schizophreniaMost of the recently available state of the art quantitative imaging tools still use cross sectional methods to analyze repeat ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Medications for Synthetic Cannabinoid Abuse
SBC: PAFOSPharma, LLC Topic: R41PROJECT SUMMARY ABSTRACT In response to PAthis Phase I STTR proposal will aim at developing pharmacotherapies that can act aslife savermedications to counteract the neurotoxic effects of synthetic cannabinoidsSCsTowards this goalwe will synthesize CB R antagonists with fast onsets of action that can be administered in an emergency roomERsituationThe rationale is based on the successful soft agonis ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen
SBC: Arrevus, Inc. Topic: NIAIDMulti drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Novel and potent SHIP1 inhibitors for improving hematologic recovery following myelosuppressive therapies
SBC: Alterna Therapeutics, Inc. Topic: NHLBIABSTRACT Despite recent advances in targeting cancer cellschemotherapy remains a mainstay of oncologyextending survival and providing cures for many types of cancerHoweverchemotherapy that ablates or suppresses bone marrow cells can be debilitating even when combined with autologous hematopoietic stem cell transplantationHSCTThe treatment causes severe side effects such as anemianeutropenia and th ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health